The Role Biologics & Biosimilars Can Play In Healthcare
WHY WE’RE TALKING BIOLOGICS
The following information has been compiled to help patients and their allies understand the role biologics can play in healthcare. When we reached out to our community about this topic, we found gaps in knowledge that needed attention.
In an effort to close those gaps, we have curated information from the most reliable sources on the subject. Our hope is that this information will lead you to have more productive conversations with your healthcare team that will open doors to new avenues of treatment.
- What are biologics and biosimilars?
- What makes them different from other drugs?
- What role can they play in your health?

FREE E-BOOK
How to Make Informed Decisions about Biologic Drugs in Your Treatment Plan
Biosimilars are biologic medicines that are highly similar to the original biologic medicine,sometimes we refer to this as the “name brand.” For the purposes of this e-book, we will refer to them as originator biologics.
e-book authors
- Surabhi Dangi-Garimella, Ph.D., Principal, SDG AdvoHealth, LLC
- Jim Sliney Jr., Director of Patient Outreach, Patients Rising University
Listen to our Podcast Episode about Biosimilars
Podcast hosts Terry Wilcox and Robert “Dr. Bob” Goldberg review what biosimilars are, explore their relationship to drug prices, and discuss the changing role of biosimilars in healthcare and the marketplace.
SURVEY RESULTS
Patient Attitudes around Cost, Safety & Efficacy
Patient Survey Report
Survey Results Infographic
Important Articles & Insights
Videos Addressing Biologics & Biosimilars Concerns
The Patient Perspective: Christina
Crossfit competitor and triathlete Christina Wolffe shares her experience using a biosimliar to manage Type 1 Diabetes.
Webinar & Panel Discussion
Terry Wilcox interviews two patients who have experience using biosimilars to treat their conditions.
Patients Rising Discussion Lab: Towards a Biosimilar Future – Safety, Savings, Solutions
Biosimilars represent at once a breakthrough innovation on behalf of patients and a gateway solution that can address the challenges of cost and access. That’s why our Discussion Lab (virtual) will focus on the extraordinary potential of these medicines, as well as how misaligned market incentives and misinformation discourage the use of this and other lower-priced alternatives. We will also explore the policy and educational choices that can encourage new and expanded utilization — and take permanent strides towards a biosimilar future.